title: Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions.
abstract: BACKGROUND
  Zollinger-Ellison syndrome and idiopathic hypersecretion are gastrointestinal hypersecretory conditions requiring long-term maintenance.
  
  
  OBJECTIVE
  The safety and efficacy data for short-term (6-month) treatment of Zollinger-Ellison syndrome and idiopathic hypersecretion with oral pantoprazole were previously published. This study extends the initial observations to 3 years.
  
  
  METHODS
  The primary efficacy end point for this report was the control of gastric acid secretion in the last hour before the next dose of oral pantoprazole (acid output of <10 mmol/h; <5 mmol/h in subjects with prior acid-reducing surgery). Dose titration was permitted to a maximum of 240 mg per 24 h.
  
  
  RESULTS
  Twenty-four subjects completed the study. The acid output of 28 of 34 subjects was controlled at initial enrolment. The mean acid output rates were <10 mmol/h throughout the 36 months of treatment for 90-100% of the patients. The majority of the patients were controlled with b.d. doses of 40 or 80 mg pantoprazole at 36 months (acid output was controlled in 24 of 24 subjects). Pantoprazole was generally well tolerated with minimal adverse events reported.
  
  
  CONCLUSIONS
  Maintenance oral pantoprazole therapy up to 3 years at dosages of 40-120 mg b.d. was effective and well tolerated in patients with Zollinger-Ellison syndrome and other hypersecretory conditions.
authors.affiliation: Department of Medicine, Division of Gastroenterology, University of Pennsylvania Medical Center, Philadelphia, PA, USA.
authors.forename: D C
authors.initials: DC
authors.lastname: Metz
authors.forename: G M
authors.initials: GM
authors.lastname: Comer
authors.forename: E
authors.initials: E
authors.lastname: Soffer
authors.forename: C E
authors.initials: CE
authors.lastname: Forsmark
authors.forename: B
authors.initials: B
authors.lastname: Cryer
authors.forename: W
authors.initials: W
authors.lastname: Chey
authors.forename: J R
authors.initials: JR
authors.lastname: Pisegna
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000284:Administration, Oral; D000368:Aged; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005744:Gastric Acid / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077402:Pantoprazole; D011446:Prospective Studies; D013454:Sulfoxides / Q000627:therapeutic use*; D016896:Treatment Outcome; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy*
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D013454:Sulfoxides; D000077402:Pantoprazole; D009853:Omeprazole